Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537765 | 0.97 | ADRB2 (0.41) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL5909092 | 0.94 | ADRB2 (0.39) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL5073591 | 0.90 | ADRB2 (0.36) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL10646386 | 0.90 | ADRB2 (0.36) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL5239732 | 0.79 | — | — | |
| SCHEMBL27996607 | 0.78 | ADRB2 (0.39) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL133600 | 0.78 | — | — | |
| SCHEMBL128741 | 0.76 | ADRB2 (0.38) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL17048695 | 0.76 | ADRB2 (0.38) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL27705656 | 0.76 | TSHR (0.39) | ADRB2ADRB1ADRB3TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8282872-B2 | (Meth)acrylate compound, curable composition using the same, curable composition for photo-nanoimprints, cured product of curable composition and method for manufacturing cured product | FUJIFILM CORPORATION (JP) | 2012-10-09 | — | — | US | disclosed |
| US-20110003909-A1 | (METH)ACRYLATE COMPOUND, CURABLE COMPOSITION USING THE SAME, CURABLE COMPOSITION FOR PHOTO-NANOIMPRINTS, CURED PRODUCT OF CURABLE COMPOSITION AND METHOD FOR MANUFACTURING CURED PRODUCT | FUJIFILM CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-20100244328-A1 | CURABLE COMPOSITION FOR PHOTOIMPRINT, AND METHOD FOR PRODUCING CURED PRODUCT USING SAME | FUJIFILM CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100133728-A1 | CURABLE COMPOSITION FOR PHOTOIMPRINT, AND METHOD FOR PRODUCING CURED PRODUCT USING SAME | FUJIFILM CORPORATION (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100121013-A1 | CURABLE COMPOSITION FOR PHOTOIMPRINT, ITS CURED PRODUCT AND PRODUCTION METHOD FOR IT, AND COMPONENT OF LIQUID-CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121013-A1 | CURABLE COMPOSITION FOR PHOTOIMPRINT, ITS CURED PRODUCT AND PRODUCTION METHOD FOR IT, AND COMPONENT OF LIQUID-CRYSTAL DISPLAY DEVICE | MBTD1, CRY1, CCNT1 | ADRB2 4556/4885ADRB1 4134/4885ADRB3 4718/4885 |
| US-20110003909-A1 | (METH)ACRYLATE COMPOUND, CURABLE COMPOSITION USING THE SAME, CURABLE COMPOSITION FOR PHOTO-NANOIMPRINTS, CURED PRODUCT OF CURABLE COMPOSITION AND METHOD FOR MANUFACTURING CURED PRODUCT | DNMT3A, DOT1L, PDE6D | ADRB2 4202/4885ADRB1 3620/4885ADRB3 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.